Eli Lilly's Oral Small-Molecule GLP-1 RA Orforglipron Granted IND Approval in China for Hypertension in Adults with Obesity or Overweight
Eli Lilly
Global Pharmaceutical R&D and Production Company
▲August 1-22025 Biomedical Innovation ExpoScan to Register
Note:This article does not constitute any investment opinions or suggestions., subject to official/company announcements;This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted must obtain authorization.
5Month6Day,CDEThe official website shows that byEli Lilly and CompanyDeclaredOrforglipronCapsule Receives Implicit Approval Through Clinical Trials, Indications are:For the treatment of hypertension in adult obese or overweight patients。
OrforglipronIs an investigational, once-daily oral small molecule (non-peptide) glucagon-like peptide – 1Receptor Agonist (GLP-1 RA). This medication can be taken at any time of the day without restrictions on food or drink.
This year4In the month, Eli Lilly and Company announcedOrforglipronCapsule3Phase Clinical StudyACHIEVE-1The positive top-line results of the study, which evaluatedorforglipronCompared with placebo, blood glucose control remains poor despite dietary control and exercise.2Safety and effectiveness in patients with type diabetes.
The trial randomized 559 patients in the United States, China, India, Japan, and Mexico to receive 3mg, 12mg, or 36mg of orforglipron or placebo in a 1:1:1:1 ratio. The aim of the study was to demonstrate that orforglipron (3mg, 12mg, 36mg) could significantly reduce glycated hemoglobin (A1C) levels from baseline compared to the placebo group after 40 weeks in patients with type 2 diabetes who were not receiving insulin therapy and had not used any diabetes medications within at least 90 days prior to the first visit. The study results showed:
Mean HbA1c levels in each dose group (A1C) The decrease was1.3%To1.6%
For the key secondary endpoint, at the highest dose, once dailyOrforglipronAchieved an average weight loss7.3kg（7.9%）
ACHIEVE-1In ResearchorforglipronThe overall safety and tolerability of the injection typeGLP-1Drug Consistency
Copyright Statement: This article is reproduced fromPharma CMC，Media or individuals who do not wish to be reproduced can contact us, and we will delete it immediately.
Conference Recommendation | Click to View Details
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Rooted in Shanghai and radiating globally, PharmaCircle, as a biopharmaceutical industry-level strategic platform, is on a mission to "enable the borderless flow of intelligence and networks." It has built a comprehensive industrial chain empowerment system covering drug research and development, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource connections, industry think tanks, and ecosystem communities—it creates the infrastructure for the flow of pharmaceutical value in China.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for leapfrog growth of enterprises.